First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

10.1177/1758835919836374

Saved in:

Bibliographic Details
Main Authors:	Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Review
Language:	English
Published:	SAGE PUBLICATIONS LTD 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218616
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1177/1758835919836374